Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2B6 | P20813 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL85750 | 1.00 | CYP2B6 (0.39) | CYP2B6 | |
| SCHEMBL85331 | 0.97 | CYP2B6 (0.36) | CYP2B6 | |
| SCHEMBL12359962 | 0.90 | CYP2B6 (0.31) | CYP2B6 | |
| SCHEMBL85659 | 0.88 | CYP2B6 (0.30) | CYP2B6 | |
| SCHEMBL20436456 | 0.87 | CYP2B6 (0.42) | CYP2B6 | |
| SCHEMBL85346 | 0.83 | — | — | |
| SCHEMBL22756187 | 0.83 | CYP2B6 (0.39) | CYP2B6 | |
| SCHEMBL12211001 | 0.80 | — | — | |
| SCHEMBL1800588 | 0.77 | CYP2B6 (0.37) | CYP2B6 | |
| SCHEMBL24410793 | 0.75 | GRIN2D (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912647-B2 | Diversity-oriented synthesis of N,N,O-trisubstituted hydroxylamines from alcohols and amines by N—O bond formation | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230158010-A1 | LUMINALLY-ACTING N-(PIPERIDIN-4-YL)BENZAMIDE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-25 | — | — | US | disclosed |
| US-20210363098-A1 | DIVERSITY-ORIENTED SYNTHESIS OF N,N,O-TRISUBSTITUTED HYDROXYLAMINES FROM ALCOHOLS AND AMINES BY N-O BOND FORMATION | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2021-11-25 | — | — | US | disclosed |
| EP-2716635-B1 | Compounds which selectively modulate the CB2 receptor | BOEHRINGER INGELHEIM INT (DE) | 2017-02-01 | — | — | EP | disclosed |
| US-9216980-B2 | Methods of use of diazacarbazoles for treating cancer | GENENTECH, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20150087630-A1 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER | GENENTECH, INC. (US) | 2015-03-26 | — | — | US | disclosed |
| US-8957063-B2 | Amine and ether compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2015-02-17 | — | — | US | disclosed |
| US-8957063-B2 | Amine and ether compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2015-02-17 | — | — | US | disclosed |
| US-8735430-B2 | Compounds which selectively modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| US-20120136001-A1 | SUBSTITUTED OXINDOLE DERIVATIVES, MEDICAMENTS CONTAINING THE LATTER AND USE THEREOF | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2012-05-31 | — | — | US | disclosed |
| US-8129389-B2 | Substituted oxindole derivatives, medicaments containing the latter and use thereof | ABBOTT GMBH & CO. KG (DE) | 2012-03-06 | — | — | US | disclosed |
| US-20110257194-A1 | SUBSTITUTED OXINDOL DERIVATIVES AND MEDICAMENTS CONTAINING THE SAME | ABBOTT GMBH & CO. KG (DE) | 2011-10-20 | — | — | US | disclosed |
| US-20110190256-A1 | Amine and Ether Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | US | disclosed |
| US-20110136869-A1 | Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-09 | — | — | US | disclosed |
| US-7951807-B2 | Substituted oxindol derivatives and medicaments containing the same | ABBOTT GMBH & CO. KG (DE) | 2011-05-31 | — | — | US | disclosed |
| US-20110118230-A1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. | 2011-05-19 | — | — | US | disclosed |
| US-20100048570-A1 | THIAZOLIDINE DERIVATIVES AND METHODS FOR THE PREPARATION THEREOF | Kainos Medicine, Inc (KR) | 2010-02-25 | — | — | US | disclosed |
| US-20090186904-A1 | Substituted Oxindole Derivatives, Medicaments Containing the Latter and Use Thereof | ABBOTT GMBH & CO. KG | 2009-07-23 | — | — | US | disclosed |
| US-20090005397-A1 | Substituted Oxindol Derivatives and Medicaments Containing the Same | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210363098-A1 | DIVERSITY-ORIENTED SYNTHESIS OF N,N,O-TRISUBSTITUTED HYDROXYLAMINES FROM ALCOHOLS AND AMINES BY N-O BOND FORMATION | ADH5, ADH1A, NAT1 | CYP2B6 190/4885 |
| US-20090005397-A1 | Substituted Oxindol Derivatives and Medicaments Containing the Same | OXTR, AVPR2, AVPR1B | CYP2B6 2698/4885 |
| US-20110257194-A1 | SUBSTITUTED OXINDOL DERIVATIVES AND MEDICAMENTS CONTAINING THE SAME | OXTR, AVPR2, AVPR1B | CYP2B6 2139/4885 |
| US-20110118230-A1 | DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | CYP2B6 3474/4885 |
| US-20110190256-A1 | Amine and Ether Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, GPR18 | CYP2B6 626/4885 |
| US-20230158010-A1 | LUMINALLY-ACTING N-(PIPERIDIN-4-YL)BENZAMIDE DERIVATIVES | HTR4, HTR1A, HTR1D | CYP2B6 732/4885 |
| US-20090186904-A1 | Substituted Oxindole Derivatives, Medicaments Containing the Latter and Use Thereof | OXTR, AVPR2, AVPR1B | CYP2B6 2847/4885 |
| US-20150087630-A1 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER | IDH3B, IDH3A, EGLN3 | CYP2B6 802/4885 |
| US-11912647-B2 | Diversity-oriented synthesis of N,N,O-trisubstituted hydroxylamines from alcohols and amines by N—O bond formation | ADH5, ADH1A, NAT1 | CYP2B6 179/4885 |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | LRRK2, ADRM1, CRBN | CYP2B6 4792/4885 |
| US-20110136869-A1 | Compounds Which Selectively Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CYP2B6 563/4885 |
| US-20120136001-A1 | SUBSTITUTED OXINDOLE DERIVATIVES, MEDICAMENTS CONTAINING THE LATTER AND USE THEREOF | OXTR, AVPR2, AVPR1B | CYP2B6 2847/4885 |
| US-20100048570-A1 | THIAZOLIDINE DERIVATIVES AND METHODS FOR THE PREPARATION THEREOF | DPP4, DPP3, DPP7 | CYP2B6 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.